Celltrion Stock (068270.KS): Price, Tickers, US Listings and Research

Main businesses

• Biopharmaceuticals (antibody biosimilars such as Remsima, plus Zymfentra and contract manufacturing): 93.3% of 2025 revenue
• Chemical drugs (e.g. Godex): 6.7%
• Pipeline: further biosimilars (e.g. CT-P51 Keytruda, CT-P44 Darzalex, CT-P55 Cosentyx) and new modalities such as ADCs and multi-specific antibodies

Earnings dates

Latest results date on file: 2Q26 on Jul 27, 2026.

Next results: no date announced yet. Korean listed companies must file quarterly and half-year reports within 45 days of the period end (annual reports within 90 days), and many announce the results date on DART in advance (company IR page).

Owning it from abroad

Celltrion has no ADR, GDR or confirmed OTC line, so direct exposure is via KRX shares (068270) through a broker with Korea market access, or indirectly via Korea-focused ETFs such as EWY (check current holdings).

See buying Korean stocks by broker and Korean stocks you can buy in the US.

Largest shareholders

• Celltrion Holdings Co., Ltd.: 25.85% (as of 2026-06-30)
• National Pension Service: 7.28% (as of 2026-07-27)
• Seo Jung-jin (founder): 4.20% (as of 2026-06-30)
• Celltrion Holdings and related parties combined (common shares): 32.83% (as of 2026-09-23)

Dividends

Pays one annual year-end dividend: KRW 750 per share in cash for FY2025 (record date 2025-12-31, approved at the 2026-03-24 AGM), the same cash amount as FY2024, when it also paid 0.05 shares per share as a stock dividend. Its value-up plan (2026-03-24) targets a three-year average shareholder-return ratio of 40% for 2025-2027 and a gradual rise in cash dividends toward 30% of EBITDA minus capex; on 2026-08-31 it set a medium-to-long-term target of returning one-third of consolidated net profit through cash dividends plus cancellation of shares bought from 2026. A KRW 100bn on-market buyback runs from 2026-09-30 to 2026-12-29.